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Abstract
The Regulators of Complement Activation cluster at chromosome 1q32 contains
the genes encoding the complement regulator factor H and five factor H related
proteins. This is an area of the genome that arose from several large genomic
duplications and these low copy repeats can cause genome instability in this region.
Genomic disorders affecting these genes have been described in atypical haemolytic
uraemic syndrome, arising commonly through non-allelic homologous recombination
(NAHR). We describe a novel CFH/CFHR3 hybrid gene secondary to a de novo 6.3kb
deletion which arose through microhomology mediated end joining rather than NAHR.
We confirm a transcript from this hybrid gene and demonstrate a secreted protein
product. Lacking the recognition domain of factor H, this hybrid protein has impaired
cell surface complement regulation. That this arose as a de novo event suggests that
this is a dynamic area of the genome where further genomic disorders may arise.
Key words
Complement factor H, atypical haemolytic uraemic syndrome, non-allelic homologous
recombination, microhomology mediated end joining, complement.
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The genes encoding complement factor H (CFH) and the factor H related
proteins (CFHRs1-5) reside in a 360-kb region in the Regulators of Complement
Activation (RCA) cluster on chromosome 1q32 (figure 1a)1. This is an area of the
genome that arose from several large genomic duplications2, 3 and these low copy
repeats can cause genome instability in this region.
Mutations in CFH are the most common genetic predisposition to the thrombotic
microangiopathy, atypical haemolytic uraemic syndrome (aHUS)4. The majority of
mutations in CFH occur at the C-terminal end responsible for host polyanion binding5-7.
Several of these CFH mutations (e.g.S1191L; V1197A) have been demonstrated to be
gene conversion events between CFH and CFHR18. Non-allelic homologous
recombination (NAHR) involving CFH and CFHR1 can result in CFH/CFHR1 hybrid
genes (supplementary figure 1)9, 10. A single family with a hybrid CFH/CFHR3 gene
(factor H protein (FH) complement control protein modules (CCPs) 1-19 and FHR3
CCPs1-5) has been reported to arise through microhomology mediated end joining
(MMEJ)11 (supplementary figure 1). These genetic variants have all been
demonstrated to impair C3b/host polyanion binding on host cells thus impairing local
complement regulation5, 8, 11.
Recently a “reverse” CFHR1/CFH hybrid gene arising through NAHR has been
described in aHUS. This encodes a FHR1 where the C terminal CCPs are replaced
by the C terminal CCPs of FH12, 13. Unlike previously reported hybrid proteins, this
does not impair FH cell surface binding, but instead acts as a competitive inhibitor of
FH13.
In this study we report a novel CFH/CFHR3 hybrid gene arising through MMEJ
which impairs cell surface complement regulation.
An 8 month old boy presented with a diarrhoeal illness; on admission creatinine
was 52 μmol/L and urea 11.1 μmol/L. A blood film demonstrated a microangiopathic 
haemolytic anaemia (MAHA) and lactate dehydrogenase (LDH) was 5747U/L. Stool
culture was positive for E.Coli O157:H7 and a diagnosis of Shiga toxin-producing
E.coli (STEC) HUS was made. He did not require renal replacement therapy and did
not receive plasma exchange. He was discharged 2 weeks later with a creatinine of
107 μmol/L. He was readmitted 2 weeks later with an upper respiratory tract infection. 
Creatinine on readmission was 141 μmol/L, urea 20.6 μmol/L, LDH 2398 U/L, platelets 
128 x 109/L with evidence of a MAHA on blood film. This relapse suggested a
diagnosis of aHUS rather than STEC HUS. Serum complement levels were within the
normal range: C3 1.05g/L (0.68-1.80g/L); C4 0.30g/L (0.18-0.60g/L); and FH 0.51g/L
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(0.35-0.59g/L). He commenced plasma exchange and required 3 sessions of
haemofiltration. A renal biopsy confirmed a thrombotic microangiopathy (figure 2).
Creatinine returned to a baseline of ~100 μmol/L. He was treated with weekly plasma 
exchange for three and a half years prior to starting Eculizumab on which he has been
maintained for three years. Creatinine is currently 200 μmol/L and there have been no 
further episodes of aHUS while on treatment with Eculizumab (supplementary figure
5).
Sanger sequencing of aHUS-associated genes (CFH, CFI, CFB, CD46, C3,
THBD and DGKE) did not reveal any mutations, although heterozygosity was found
for the common Y402H polymorphism (rs1061170) in CFH. Multiplex ligation-
dependent probe amplification (MLPA) of CFH and the CFHRs revealed a deletion in
the CFH gene (figure 1b). To define the extent of the deletion and to define the
breakpoint Sanger sequencing of genomic DNA was undertaken. This showed a 6.3kb
deletion extending from CFH intron 20 to the CFH 3’ intergenic region incorporating
exons 21, 22 and 23 of CFH (figure 1c). Directly flanking the breakpoint was a 7bp
region of microhomology (figure 1d). The deletion was not detected in either parent
suggesting that this was a de novo event.
We hypothesised that the loss of CFH exons 21, 22, 23 and the 3’UTR of CFH
would lead to aberrant splicing. In silico analysis showed that the next acceptor splice
site, following the CFH exon 20 donor site, was 5’ of CFHR3 exon 2, thus potentially
producing a transcript for a hybrid CFH/CFHR3 gene (supplementary figure 2).
Messenger RNA for this putative hybrid CFH/CFHR3 gene was confirmed by
amplifying patient and control cDNA with CFH and CFHR3 specific primers. This
demonstrated a product in the patient and not in healthy controls (figure 1e).
To confirm that this hybrid transcript led to the synthesis and secretion of a
hybrid protein, western blotting was performed using a series of epitope-defined anti-
FH monoclonal antibodies (figure 3a). An initial blot probed with OX24, a FH CCP5-
specific antibody, demonstrated, in addition to FH, two additional bands only in the
patient (figure 3b). The species at ~160kDa was consistent with the predicted intact
hybrid FH/FHR3. A species at ~120kDa, was hypothesised to be a degradation
product. No abnormal bands were detected in either parent (supplementary figure 3a).
A FH C-terminal specific antibody (L20/3) did not reveal additional aberrant bands,
indicating that these protein species lacked FH CCP20 (Fig 3c). Genotyping showed
the patient to be heterozygous for the Y402H polymorphism in FH. This allowed the
use of monoclonal antibodies specific for histidine or tyrosine in CCP7 of FH14. The
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normal allele’s product reacted to the histidine specific mAb (MBI7) and gave a single
band of ~150kDa consistent with FH. The hybrid allele reacted to the tyrosine specific
mAb (MBI6), demonstrating a doublet at ~160Kda (figure 3d). FHR3 is known to be
alternately glycosylated15-17 and we hypothesise that the doublet is due to an
alternately gylcosylated hybrid protein. Additionally it can be seen that the presumed
degradation product at 120kDa, is only seen using the tyrosine specific mAb,
consistent with this only arising from the hybrid protein.
To confirm these findings, FH species were purified from serum using affinity
chromatography with an OX24 mAb. These were separated by a 6% SDS PAGE prior
to trypsin digestion. Mass spectrometry was then carried out on these three purified
bands (figure 4a). Peptide species identified from the ~160kDa band confirmed that
this was a hybrid FH/FHR3 protein. Protein fragments from the 150kDa band were
consistent with FH. Fragments from CCPs 5, 6, 8, 9 and 14 of FH were seen in the
band at ~120kDa. Coverage at CCP7 was insufficient to determine whether there was
a tyrosine or histidine at position 402. The western blot analysis and mass
spectrometry data together show that breakdown products from only the hybrid protein
are seen in serum.
To examine the functional significance, the FH/FHR3 hybrid protein was purified
from serum using affinity chromatography with an MBI6 mAb followed by gel filtration
(supplementary figure 3b). The FH/FHR3 hybrid protein displayed both impaired cell
surface decay acceleration (figure 4b) and cofactor activity (figure 4c).
Thus, in this study we demonstrate a deletion in the RCA cluster resulting in a
novel de novo CFH/CFHR3 hybrid gene. Microhomology in the sequence flanking the
breakpoint suggests that the deletion has occurred through MMEJ. Genomic disorders
affecting CFH and the CFHRs as a result of non-allelic homologous recombination,
are found in ~4.5% of aHUS patients. In contrast, only one case of a genomic disorder
secondary to MMEJ has been described11.
We have demonstrated that the product of this gene, a 22 CCP domain protein,
is secreted albeit with degradation fragments present in the serum suggesting
impaired stability of the protein. Functional analysis of the purified FH/FHR3 protein
demonstrated impaired cell surface complement regulation.
This FH/FHR3 hybrid protein is similar to that described by Francis et al.11 in that
in both the C-terminal end of FH is replaced by all 5 CCPs of FHR3 (supplementary
figure 1). Whilst both hybrids lack CCP20 of FH responsible for cell surface protection,
the hybrid reported here also lacks CCPs 18 and 19.
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The functional role of FHR3 is unclear, with various regulatory activities being
suggested16, 18. Unsurprisingly, given its high homology with CCP7 of FH, FHR3 binds
to heparin16. FHR3 also binds to C3b and C3d through CCPs4-516, 19. Competition
between FHR3 and FH for surface bound C3b has been described18. The hybrid
described by Francis et al. demonstrated normal fluid phase complement regulatory
activity but a profoundly reduced cell surface complement regulatory activity11.
That such a FH/FHR3 hybrid should lack cell surface regulatory activity is not
surprising. Both these hybrids lack the CCP 20 domain of FH responsible for cell
surface localisation6. Additionally, structural analysis has revealed a specific hairpin
structure suggesting a model whereby cell surface bound C3b is engaged by both
CCP1-4 and CCP19-20 of FH concurrently20. The elongation of FH by the addition of
extra CCPs would prevent such an orientation.
Although the initial presentation of disease was seen in association with a STEC,
the rapid relapse suggested aHUS rather than STEC HUS and this was confirmed by
the finding of the CFH/CFHR3 hybrid gene. In individuals carrying mutations in
complement genes, additional triggers (e.g. pregnancy21, infection22) are required for
disease to manifest4, 22. In this case, STEC served to unmask the genetic
predisposition to disease as in 2 previously reported cases of STEC triggered aHUS 23.
In summary we describe a deletion in the RCA cluster arising through MMEJ
which results in a novel CFH/CFHR3 hybrid gene. That, this arose as a de novo event
suggests that this is a dynamic area of the genome where we should expect further
genomic disorders.
Concise Methods
The study was approved by Newcastle and North Tyneside 1 Research Ethics
Committee, and informed consent was obtained in accordance with the Declaration of
Helsinki.
Complement Assays
C3 and C4 levels were measured by rate nephelometry (Beckman Coulter Array
360). FH levels were measured by radial immunodiffusion (Binding Site). Screening
for FH autoantibodies was undertaken using ELISA as described previously24.
Genetic Analysis and Multiplex ligation-dependent probe amplification
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Mutation screening of CFH25, CFI26, CFB27, MCP28, C329, and DGKE30 was
undertaken using Sanger sequencing as previously described. Screening for genomic
disorders affecting CFH, CFHR1, CFHR2, CFHR3, and CFHR5 was undertaken using
multiplex ligation-dependent probe amplification (MLPA) in both the affected individual
and 500 normal controls as previously described11. A proprietary kit from MRC Holland
(www.mlpa.com; SALSA MLPAkit P236-A1 ARMD) was supplemented by specific in
house CFH probes (supplementary). GeneMarker software (Version 1.90) was used to
calculate dosage quotients.
Genomic breakpoint analysis
To identify the breakpoint of the deletion that resulted in the CFH/CFHR3 hybrid
gene, genomic DNA was amplified using a forward primer specific for CFH in exon 20
and a reverse primer in the CFH 3’ region (figure 1c). The sequence of the forward
primer was GTAACTGTTATCAGTTGATTTGC, and the reverse was
ACGGATTGCATGTATAAGTG. The product was then sequenced using direct
fluorescent sequencing.
Confirmation of CFH/CFHR3 RNA product
mRNA was extracted from peripheral blood lymphocytes of the patient and
cDNA was prepared. This was amplified using a forward primer in CFH exon 20
(TGGATGGAGCCAGTAATGTAACATGCAT) and a reverse primer in CFHR3 exon 2
(GAAATAGACCTCCATGTTTAATGTCTG) (figure 1c). The PCR product was detected
in an ethidium bromide–stained 1.5% agarose gel
Western blotting
Detection of abnormal protein products in serum arising as a consequence of the
deletion was undertaken by Western blotting. Sera was diluted 1/100 and under non-
reducing conditions, electrophoresed on 6% SDS-PAGE gel and transferred onto
nitrocellulose. Monoclonal antibodies of known specificity to FH (OX24, CCP 5; L20/3,
CCP 20, MBI-6, CCP7 402Y, MBI-7 CCP7, 402H) were used with sheep anti–mouse-
Ig HRP (Jackson Immuno Research), at dilutions 1:2000 (primary Ab) and 1:4000
(secondary Ab) (supplementary methods). Following washes in 1xTBST, blots were
developed using Pierce ECL Western blotting substrate (Thermo Scientific).
Purification of factor H species
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FH species (WT FH from normal allele, FH/FHR3 hybrid and FH/FHR3
breakdown product all with CCP5 of FH) were purified from serum with affinity
chromatography using immobilised monoclonal antibody to FH (OX24), on a 1 mL
HiTrap NHS HP column (GEHealthcare). Following washing with PBS, the bound
proteins were then eluted using 0.1M glycine pH2.7. The eluted material was pooled
and concentrated for analysis by mass spectrometry.
The FH/FHR3 hybrid protein was purified from patient serum with affinity
chromatography using immobilised monoclonal antibody to FH CCP7 402Y (MBI6)31,
on a 1 mL HiTrap NHS HP column (GEHealthcare). Following washing with PBS, the
bound proteins were eluted using PBS/diethylamine (50mM). Subsequently the
FH/FHR3 protein was purified from its degradation product and FHL1 using a
Superdex 200 size exclusion column. We also purified WT FH protein from a healthy
control. FH or FH/FHR3 hybrid protein purified using the MBI6 column was used for
cofactor and decay acceleration assays.
Mass Spectrometry
A 6% SDS PAGE was run and the 3 bands identified by coomassie staining were
excised from the gel as indicated in figure 4a. Trypsin digest and mass spectrometry
were then undertaken (supplementary methods).
Cell surface decay acceleration assays
Decay acceleration on sheep erythrocytes was performed as previously described32
and in supplementary methods. Briefly, FH/FHR3 hybrid from the patient and FH from
control were purified by immuno-affinity chromatography as above and gel filtered into
PBS. Alternative pathway convertase (C3bBb) was formed on sheep erythrocytes.
Cells were incubated for 15 minutes with 1.24nM to 50nM patient FH/FHR3 hybrid or
control FH. The molar concentration of the purified patient FH/FHR3 was estimated
using the extinction co-efficient (272170 M.cm-1) while the extinction coefficient of FH
(246800 M.cm-1) was used for the control . Lysis was initiated with 4% normal human
serum, depleted of factor B and FH (NHSΔBΔH). Maximal lysis was achieved by 
adding NHSΔBΔH to no FH wells (buffer only). To determine the amount of lysis, cells 
were pelleted by centrifugation, and haemoglobin release was measured at 420 nm
(A420). Percentage of inhibition of lysis in the presence of increasing concentrations
was defined as: (A420[buffer only]-A420[FH]) / A420[buffer only] *100%.
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Cell surface cofactor assays
Cofactor activity on sheep erythrocytes was performed as previously described32.
Briefly washed C3b-coated sheep erythrocyte cells were resuspended in AP buffer
and incubated with an equal volume of a range of concentrations of FH/FHR3 hybrid
and WT FH and 2.5 μg/ml factor I (CompTech) for 8 minutes at 25°C. After three 
washes in AP buffer, AP convertase was formed on the remaining C3b. Lysis was
initiated with 4% NHSΔBΔH. Again, cells were pelleted and haemoglobin release was 
measured at 420nm. Percentage of inhibition from lysis was calculated by the formula
(A420[buffer only]-A420[FH])/A420 [buffer only]*100%.
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Figure Legends
Figure 1 (a) Genomic organisation of the RCA cluster region containing the CFH and
CFHR genes. (b) Multiplex ligation-dependent probe amplification of CFH, CFHR3,
CFHR1, CFHR2 and CFHR5 demonstrating the copy number ratio. The dotted lines
represent ratios considered within the normal range. (c) Identification of break point.
Genomic DNA was amplified using a forward primer specific for CFH exon 20 (1f) and
a reverse primer in the CFH 3’ region intergenic region (1r) and sequenced. The
deletion of exons 21, 22 and 23 of CFH is demonstrated (shaded box) and the
breakpoint highlighted. (d) The CFH and CFHR3 sequence flanking the breakpoint.
The 7 base pair area of microhomology is demonstrated (bold, boxed) (e)
Confirmation of hybrid CFH/CFHR3 hybrid mRNA. A message for the hybrid
CFH/CFHR3 gene was confirmed by amplifying patient and control cDNA with cross
CFH and CFHR3 gene primers (filled arrows 2f and 2r). The agarose gel
demonstrates amplified cDNA. The patient lane shows an amplified product consistent
with a hybrid CFH/CFHR3 gene, which is not present in either control cDNA.
Figure 2 Renal biopsy of the patient demonstrating thrombi (arrows) on capillary loops
(a) H&E (b) Masson trichrome. A developing membranoproliferative pattern of injury
can be seen in (c) characterised by capillary loop double contours (arrows, silver
counter stained H&E, x400).
Figure 3 (a) The protein product of wild type FH and the predicted FH/FHR3 hybrid
protein consisting of CCPs1-17 of FH and CCP1-5 of FHR3. The CCPs originating
from FHR3 are highlighted in grey. The patient is heterozygous for a common
polymorphism in CCP7 of FH (Y402H). Binding epitopes for the monoclonal antibodies
are shown: Ox24-CCP5; MBI-7- CCP7 amino acid 402 histidine variant; MBI-6- CCP7
amino acid 402 tyrosine variant; L20/3-CCP20. (b) Serum Western blot using OX24
demonstrating 2 additional bands in the patient in addition to FH. The upper band is
consistent with the predicted size of the FH/FHR3 hybrid. (c) Serum Western blot
using L20/3. When using this FH C-terminal specific antibody no additional bands are
seen, consistent with the hybrid protein lacking CCP18-20. (d) Serum Western blot
using MBI-7. This demonstrates that the patient has a normal allele producing FH with
the Histidine at amino acid 402. (e) Serum Western blot using MBI-6. The patient has
3 additional bands and no wild type FH band. This is consistent with the FH/FHR3
hybrid protein carrying the Tyrosine amino acid at position 402. The two additional
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upper bands represent differentially glycosylated hybrid protein, consistent with that
seen in the native FHR3. There is a faint degradation product only detected with the
MBI-6 antibody. This is consistent with the breakdown product being generated only
from the hybrid protein and suggests a less stable protein product. The controls were
unaffected, unrelated, genotyped samples. In (b) and (c) a sample from an individual
heterozygous at Y402H was used. In (d) and (e) samples from individuals
homozygous for Y402 (Y/Y); homozygous for H402 (H/H); or heterozygous (Y/H) were
used.
Figure 4. (a) Mass spectrometry of purified proteins. The FH, FH/FHR3 hybrid and the
degradation product were purified using affinity chromatography with an Ox24 column.
These FH species were separated by 6% SDS PAGE, stained using Coomassie, cut
from the gel (left), and submitted for trypsin digest and mass spectrometry. Peptides
sequences identified using mass spectrometry are indicated *. The peptides detected
in the hybrid degradation product by mass spectrometry are annotated on a full length
FH/FHR3 hybrid protein. CCPs which cannot be directly inferred from mass
spectrometry data are outlined with a dashed line. A molecular weight of ~120kDa is
consistent with a ~17 CCP protein. (b) Decay acceleration assays on sheep
erythrocytes. The purified FH/FHR3 hybrid from patient demonstrated impaired cell
surface complement regulation compared to wild type (WT) FH purified from control.
Alternative pathway convertase (C3bBb) was formed on sheep erythrocytes. Cells
were incubated for 15 minutes with dilutions of purified FH/FHR3 hybrid and WT FH
before triggering lysis with NHSΔBΔH. Maximal lysis occurs in buffer-only (0 mM FH) 
conditions. Addition of WT FH caused decay of the C3 convertase and decay of
convertase resulting in inhibition of lysis. The FH/FHR3 hybrid was up to 2-fold less
efficient at inhibiting lysis. (C) C3b cofactor activity on sheep erythrocytes. WT FH and 
purified FH/FHR3 hybrid were tested for the ability to act as a cofactor for factor I–
catalyzed inactivation of C3b deposited on the surfaces of sheep erythrocytes. The C3
convertase (C3bBb) was formed on residual C3b and lysis was triggered by adding
NHSΔBΔH . Maximal lysis occurs in the presence of buffer only (0 mM FH). The 
addition of WT FH and factor I produces iC3b which decreases convertase formation
and subsequent lysis, which is shown as increasing amounts of inhibition of lysis
(expressed as percentage of maximal lysis) after incubation with factor I and WT FH
CFH/CFHR3 hybrid gene in aHUS
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(black circles) or FH/FHR3 hybrid (white circles). The FH/FHR3 hybrid can be seen to
be markedly less active than WT.
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Supplementary Figure 3 (a) Reduced Western blot of parental serum using a polyclonal anti FH (Calbiochem)
demonstrating a single FH species with no additional bands. The absence of FH/FHR3 hybrid or FH/FHR3 degradation
product in either parent is consistent with the genetic data confirming a de novo deletion. (b) Non-reduced SDS PAGE
demonstrating purification of the FH/FHR3 hybrid protein. The FH/FHR3 hybrid protein was purified from serum using affinity
chromatography with an MBI6 mAb followed by gel filtration. A WT FH control known to carry the tyrosine amino acid at
position 402 was purified in an identical manner.
Supplementary figure 4
(a) (b)
α1
β
α'
Supplementary Figure 4 (a) Heparin binding profile of purified FH/FHR3 hybrid protein. Purified proteins from patient
(FH/FHR3) and control FH (402Y) were bound to a HiTrap heparin column and eluted with NaCl. The FH/FHR3 hybrid (black)
eluted at 325mM and FH (grey) at 357mM, indicating reduced binding of the hybrid. Unlike the FH/FHR3 hybrid reported
here, the previously reported FH/FHR3 hybrid (Francis et al.) had increased heparin binding. This likely reflects the additional
loss of CCPs18-19 in the Challis et al. hybrid. In both cases there was impaired cell surface decay acceleration and cofactor
activity. Dashed line indicates salt gradient. (b) Fluid phase cofactor assay. Equimolar concentrations (50nM) of WT FH and
FH/FHR3 were used. In the fluid phase factor I cleaves C3b, in the presence of the FH/FHR hybrid, to iC3b as seen by the
generation of the α1 band at equivalent levels to WT FH.
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Supplementary Figure 5- Graph of eGFR against time post presentation. Haemodialysis (HD) was required at the time of
the second presentation with aHUS. Over the next ~3.5 years he received weekly plasma exchange with intensified
treatment during periods of clinical relapse (>500 PE treatments). After ~3.5 yrs peritoneal dialysis was instituted due to
hyperkalaemia, with a creatinine consistently above 250 μmol/L. Plasma exchange was replaced with Eculizumab after one
month on dialysis. After ~3.5 years peritoneal dialysis was stopped and creatinines have been in the range 190-230 μmol/L.
Since initiation of Eculizumab there have been no episodes of clinical relapse of aHUS.
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Supplementary methods
CFH and CFHR5 MLPA probe hybridization sequences
Gene Exon Left Primer (5’ 3’) Right Primer (5’  3’)
CFH 1 CACAATTCTTGGAAGAGGAGAACTG GACGTTGTGAACAGAGTTAGCTGG
2 TGACAGGTTCCTGGTCTGACCAA ACATATCCAGAAGGCACCCAGGCT
3 CGTTTTAGAAAGGCCCTGTGGACATCCTGGA
GATACTCCTTTTGGTACTTTTACCCTTACAG
GAGG
4 GGTATCAATTGCTAGGTGAGATTAATTACCGTGA
ATGTGACACAGATGGATGGACCAATGATAT
TCCTATATGTGAAGG
TAG
5 GTGCAATGGAACCAGATCGGGAATA CCATTTTGGACAAGCAGTACGGTTTG
6 CATGGGTTATGAATACAGTGAAAGAGGAGA TGCTGTATGCACTGAATCTGGATGGCGTCCGTTGCCT
7 GGTGACTACTCACCTTTAAGGATTAAACACAGAACTGGAGATGAAATCACGTAC
CAGTGTAGAAATGGTTTTTATCCTGCAACCC
GGGGAAATACAGC
8 CACATTCATTGCACACAAGATGGA TGGTCGCCAGCAGTACCATGCCTC
9 GTACAGGGTAAATCTATAGAC GTTGCCTGCCATCCTGGCTACG
10 CAGAATGGGAAATGCTAATTCAGCTCCTCCAGGCAGCCCAATGGG
GCTGGTGGCTTTGAGATTATTAAACTCTTTC
TCTGCTGC
11 TGAAACATCAGGATCAATTACATGTGG GAAAGATGGATGGTCAGCTCAACC
12 GAATGCCAGAACTAAAAATGACTTCACATGGTTTAAG
CTGAATGACACATTGGACTATGAATGCCAT
GATGG
13 ACCTAATTCCGTTCAGTGCTACC ACTTTGGATTGTCTCCTGACCTCC
14 CAGTGAAGTGGTGGAATATTATTGCAATC CTAGATTTCTAATGAAGGGACC
15 GGAGGAGAGTACCTGTGGAGATATACCTGAACTTGAACATGG
CTGGGCCCAGCTTTCTTCCCCTCCTTATTA
CTATGG
16 GGAAAAGAAGGATGGATACACACAGTCTG CATAAATGGAAGATGGGATCCAGAAGTGAACTGC
17 GGCACAAATACAATTATGCCCACCTCCACCTCAGATTCC
CAATTCTCACAATATGACAACCACACTGAAT
TATCG
18 CCATGTTCACAACCACCTCAGATAGAACAC GGAACCATTAATTCATCCAGGTCTTCAC
19 GGAATTGATGGGCCTGCAATTGCAAAATGCTTAG GAGAAAAATGGTCTCACCCTCCATCATGC
20 GGATGGAGCCAGTAATGTAACATG CATTAATAGCAGATGGACAGGAAGGC
21
CTTATATAGTGTCGAGACAGATGAGTAAATA
TCCATCTGGTGAG
AGAGTACGTTATCAATGTAGGAGC
CCTTATGAAATGTTTGGGGATGAAGAAGTG
ATGTGTTTAAATGGA
AACTGGACGGAAC
22 CGTAAGTACTTTAATATTCACGTGGCTG
GAAAAATCTCTGTGATGAGTCTGATATTTCA
CTGTTTG
23 GGACAGCCAAACAGAAGCTTTATTC GAGAACAGGTGAATCAGTTGAATTTGTG
Gene Exon Left Primer (5’ 3’) Right Primer (5’ 3’)
CFHR5 1
GAGACTACCAAGCATGTTGCTCTTATT
CAGTGTAATC
CTAATCTCATGGGTATCCACTGTTGGGGG
AGAAGG
2 CCCAGGAACACTTTGTGATTTTCCAAAAATACACCATG
GATTTCTGTATGATGAAGAAGATTATAACC
C
3 CAAATTATTTGCAACACAGGATACAGC
CTTCAAAACAATGAGAAAAACATTTCGTGT
G
4 GTCATGTTCCAATTTTAGAAG CCAATGTAGATGCTCAGCC
5 CCACCTCCTCAACTCTCCAATGGTGAAGTTAAG GAGATAAGAAAAGAGGAATATGGACAC
6 GGATACATACCTGAACTCGAGTACGGTTATGTTCAGCCGTCTGTC
CCTCCCTATCAACATGGAGTTTCAGTCGAG
GTGAATTGC
7 CAGATGTTCAGACATCTTCAGATACAG GCACTCAGTCTGTATAAACGGG
8 GGGAACAATTCTGCCCACCGCCACCTCAGATACCTAATG
CTCAGAATATGACAACCACAGTGAATTATC
AGGATGG
9 CCCATTATCAGTATATCCTCCAGGGTCAACAGTGACGTACCGTTGC
CAGTCCTTCTATAAACTCCAGGGCTCTGTA
ACTGTAACATGC
10 GCTGTTGAATTCCAGTGTAAATTCC CACATAAAGCGATGATATCATCACCACC
In house MLPA probe hybridisation sequences for CFH and CFHR5.
Mass Spectrometry
The eluted material was pooled and concentrated to 30uL. This was then run on a
6% SDS PAGE, 3 bands identified by coomassie staining, were excised from the gel
as indicated in figure 4a. Proteins were reduced with 10 mM DTT (Sigma) in 100 mM
NH4HCO3, alkylated with 50 mM iodoacetamide (Sigma) in 100 mM NH4HCO3 and
digested in gel with 230ng modified trypsin (Promega) in 50 mM NH4HCO3, 1 mM
CaCl2. Peptides were extracted from the gel pieces and the digests were analysed
by LCMSMS using a Dionex U3000 nano-HPLC system (Thermo) coupled to an
Orbitrap LTQ XL(ETD) (Thermo) mass spectrometer. Peptides were separated on a
25 cm x 75 µm PepMap column (Thermo) using a 37 min water acetonitrile gradient
(0.05% formic acid). Precursor ions were detected in positive mode at 350-1600 m/z
with a resolution of 60,000 (at 400 m/z) and a fill target of 500,000 ions and a
lockmass was set to 445.120023 m/z. The five most intense ions of each MS scan
(with a target value of 10,000 ions) were isolated, fragmented and measured in the
linear ion trap. Peaklists in the Mascot generic format (*.mgf) were generated using
msconvert (proteowizard.sourceforge.net (Kessner et al., 2008)) and the ensembl
human genome (GrCh37.66) was searched using X!Tandem and the gom interface
(version 2013.09.01.1(Craig and Beavis, 2004)) with carbamidomethyl set as a fixed
modification and Met oxidation set as a variable modification. Two refinement steps
were included in the search to include deamidation and methylation artefacts as well
as protein phosphorylation, acetylation, dehydration of Thr and Ser and
carbamidomethylation of Gln, His, Asp, Glu and Lys. The protein level false positive
rate (as defined in: http://wiki.thegpm.org/wiki/False_positive_rate) in each band was
below 1%.
Preparation of serum depleted of factor B and FH
Normal human serum depleted of factor B (FB) and FH (NHSΔBΔH) was prepared 
by flowing normal human serum over immobilised monoclonal antibody to FB (JC1)
and monoclonal antibody to FH (OX24), on separate 1 mL HiTrap NHS HP columns
in series. NHSΔBΔH was collected and pooled for use in the cell surface decay and 
co-factor haemolytic assays.
Cell Surface Decay Haemolytic assay
FH and FH/FHR3 hybrid were purified as described earlier. The concentration of
purified proteins was measured at 280nm. Molarities were calculated using Beer’s
Law: A= ε L c, (where A= Absorbance, ε= Molar extinction coefficient, L= light path 
and c= Concentration). The extinction coefficients were determined, using
ProtParam (Gasteiger et al., 2005), assuming all pairs of cysteines form cystines.
The leader sequences for FH (MRLLAKIICLMLWAICVA) and FHR3
(MLLLINVILTLWVSCANG) were excluded from the analysis. The extinction
coefficient for FH was 246800 M.cm-1. To calculate the extinction coefficient for
FH/FHR3, the first 1026 amino acids from FH and the 312 amino acids from FHR3
were analysed, producing an ε of 272170 M.cm-1.
Sensitised Sheep erythrocytes (EA) were prepared by incubating 2% (vol/vol) sheep
erythrocytes [TCS biosciences] and 1:4000 anti-sheep stromal antibodies [Sigma] in
Complement Fixation Diluent (CFD) [Oxoid], at 37°C for 30 minutes. After incubation
the mixture was washed using CFD and the cells resuspended to 2% (vol/vol).
C3b was then deposited onto EA (EAC3b) by the addition of 4% NHSΔBΔH and 
6μg/ml Ornithodoros moubata complement inhibitor (OmCI) in CFD to an equal
volume of 2% (vol/vol) EA in CFD and incubated at 37°C for 20 mins. EAC3b were
washed with Alternative Pathway Buffer (AP buffer) [5mM sodium barbitone, pH 7.4,
150 mM NaCl, 7 mM MgCl2, 10mM EGTA] and resuspended to 2%.
A convertase was formed on the sheep erythrocytes by adding 2% (vol/vol) EAC3b
cells to an equal volume of AP Buffer, containing 40μg/ml Factor B [prepared in 
house] and 0.2 μg/ml Factor D [Complement Technology] and incubating for 15 
minutes at 37°C. 100μL of this convertase mixture was then added to 50 μL (1.24nM 
– 50nM) FH/FHR3 hybrid and FH (purified from patient or control), diluted in
PBS/20nM EDTA and left at room temperature for 15 minutes, to allow decay
acceleration to take place. 50µL 4% (vol/vol) NHSΔBΔH in PBS/20mM EDTA was 
then added and incubated at 37°C for 30 minutes to initiate lysis. To determine the
amount of lysis, cells were pelleted by centrifugation at 1200rpm for 3 minutes and
haemoglobin release was measured at 420nm (A420). All values were blank-
corrected, using the mean A420 of no serum controls. Maximal lysis was achieved by
adding NHSΔBΔH to no FH wells (buffer only). Percentage of inhibition of lysis in the 
presence of increasing concentrations of FH was defined as: (A420[buffer only]-
A420[FH]) / A420[buffer only] *100%.
Cell Surface Co-factor assay
FH and FH/FHR3 hybrid were purified as above. EAC3b was prepared as above. 2%
EAC3b in AP buffer were then incubated with an equal volume of AP buffer
containing a concentration range (0.6 to 50nM) of FH or FH/FHR3 hybrid and
2.5μg/ml Factor I (Complement Technology) for 8 minutes at 25°C. After three 
washes in AP buffer, a 50 μl aliquot of cells (2%) was mixed with 50 μl AP buffer 
containing FB (40 μg/ml) and FD (0.2 μg/ml) and then incubated for 15 minutes at 
25°C to form AP convertase on the remaining C3b. Lysis was developed by adding
50 ml 4% NHSΔBΔH in PBS/20mM EDTA and incubating at 37°C for 30 minutes. 
Percentage of inhibition from lysis was calculated by the formula (A420[buffer only]-
A420[fH])/A420[buffer only]*100%
Fluid phase co-factor Assay
Cofactor activity for factor I–mediated proteolytic cleavage of C3b in the fluid phase
was analysed. 3μl of C3b (5.68 μM) (Comptech), 4.5 μl of factor I (0.14μM) 
(Comptech), and 5 μL of WT FH or FH/FHR3 hybrid (0.15 μM) were made up to a 
final volume of 15 μl in PBS. A negative control using PBS instead of FH was also 
performed. The mixture was incubated at 37°C for 60 minutes and the reaction was
stopped by the addition of 2X lamelli reducing buffer to a final volume of 30 ml and
heated to 95°C for 5 minutes. The products of the reaction were then separated by
SDS-PAGE and visualised by Coomassie stain.
Factor H Antibodies used for protein detection in figure 3
Antibody Epitope Source Reference
Ox24 CCP5 Sigma-Aldrich J Exp Med.(1998) 87:451
L20/3 CCP19-20 Santa Cruz Biotechnology J Immunol.(2012)189:3528
MBI6 CCP7 402Y In house Kidney Int. (2010) 78:782
MBI7 CCP7 402H In house Kidney Int. (2010) 78:782
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